Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study

Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA

Riordan, J. R., Rommens, J. M., Kerem, B.-S., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J.-L., et al. (1989) · Science · doi:10.1126/science.2475911 · Cited by 7,418 · see citing works

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Middleton, P. G., Mall, M. A., Dřevínek, P., Lands, L. C., McKone, E. F., Polineni, D., Ramsey, B. W., Taylor-Cousar, J. L., Tullis, E., Vermeulen, F., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908639 · Cited by 2,198 · see citing works

Cystic fibrosis

Elborn, J. S. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00576-6 · Cited by 1,710 · see citing works

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Heijerman, H. G. M., McKone, E. F., Downey, D. G., Van Braeckel, E., Rowe, S. M., Tullis, E., Mall, M. A., Welter, J. J., Ramsey, B. W., McKee, C. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32597-8 · Cited by 1,414 · see citing works

Cystic fibrosis

O'Sullivan, B. P., & Freedman, S. D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60327-5 · Cited by 1,320 · see citing works

Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

Goor, F. V., Hadidaꝉ, S., Grootenhuis, P. D. J., Burton, B., Cao, D., Neuberger, T., Turnbull, A., Singh, A. K., Joubran, J., Hazlewood, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904709106 · Cited by 1,225 · see citing works

The future of cystic fibrosis care: a global perspective

Bell, S. C., Mall, M. A., Gutierrez, H., Macek, M., Madge, S. L., Davies, J. C., Burgel, P., Tullis, E., Castaños, C., Castellani, C., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30337-6 · Cited by 1,042 · see citing works

VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

Keating, D., Marigowda, G., Burr, L., Daines, C., Mall, M. A., McKone, E. F., Ramsey, B. W., Rowe, S. M., Sass, L. A., Tullis, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1807120 · Cited by 726 · see citing works

CFTR Function and Prospects for Therapy

Riordan, J. R. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142532 · Cited by 610 · see citing works

Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries

Quittner, A. L., Goldbeck, L., Abbott, J., Duff, A., Lambrecht, P., Solé, A., Tibosch, M. M., Bergsten Brucefors, A., Yüksel, H., Catastini, P., et al. (2014) · Thorax · doi:10.1136/thoraxjnl-2014-205983 · Cited by 524 · see citing works

The Cystic Fibrosis Foundation Patient Registry. Design and Methods of a National Observational Disease Registry

Knapp, E. A., Fink, A. K., Goss, C. H., Sewall, A., Ostrenga, J., Dowd, C., Elbert, A., Petren, K., & Marshall, B. C. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201511-781oc · Cited by 467 · see citing works

A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele

Zemanick, E. T., Taylor‐Cousar, J. L., Davies, J. C., Gibson, R. L., Mall, M. A., McKone, E. F., McNally, P., Ramsey, B. W., Rayment, J. H., Rowe, S. M., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202102-0509oc · Cited by 315 · see citing works

Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor

Bessonova, L., Volkova, N., Higgins, M., Bengtsson, L., Tian, S., Simard, C., Konstan, M. W., Sawicki, G. S., Sewall, A., Nyangoma, S., et al. (2018) · Thorax · doi:10.1136/thoraxjnl-2017-210394 · Cited by 214 · see citing works

Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More <i>F508del</i> Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial

Griese, M., Costa, S., Linnemann, R. W., Mall, M. A., McKone, E. F., Polineni, D., Quon, B. S., Ringshausen, F. C., Taylor-Cousar, J. L., Withers, N. J., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202008-3176le · Cited by 163 · see citing works

Pulmonary Exacerbations in Adults With Cystic Fibrosis

Stanford, G. E., Dave, K., & Simmonds, N. J. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.09.084 · Cited by 58 · see citing works

The impact of CFTR modulator therapies on CF airway microbiology

Rogers, G. B., Taylor, S., Hoffman, L. R., & Burr, L. D. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.07.008 · Cited by 56 · see citing works

Reduction of pulmonary exacerbations in young children with cystic fibrosis during the COVID‐19 pandemic

Patel, S., Thompson, M., Slaven, J. E., Sanders, D. B., & Ren, C. L. (2021) · Pediatric Pulmonology · doi:10.1002/ppul.25250 · Cited by 41 · see citing works

Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations

Munck, À., Kerem, E., Ellemunter, H., Campbell, D., Wang, L. T., Ahluwalia, N., Owen, C. A., & Wainwright, C. E. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2020.04.015 · Cited by 36 · see citing works

CFTR modulators: transformative therapies for cystic fibrosis

Dwight, M., & Marshall, B. C. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.2.281 · Cited by 32 · see citing works

Triple Therapy for Cystic Fibrosis Phe508del –Gating and –Residual Function Genotypes

Barry, P. J., Mall, M. A., & Polineni, D. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2115966 · Cited by 19 · see citing works

170 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from an open-label extension study

Griese, M., Tullis, E. D., Chilvers, M. A., Fabrizzi, B., Jain, R., Legg, J., Mall, M. A., McKone, E. F., Polineni, D., Poplawska, K., et al. (2022) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(22)00861-x · Cited by 12 · see citing works

177: Impact of elexacaftor/tezacaftor/ivacaftor therapy use on pulmonary exacerbation rates during the COVID-19 pandemic

Menten, E. R., Saroya, T. K., DiMango, E., & Keating, C. (2021) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(21)01602-7 · Cited by 3 · see citing works

Cystic fibrosis

Mall, M. A., Burgel, P., Castellani, C., Davies, J. C., Salathe, M. A., & Taylor‐Cousar, J. L. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00538-6 · Cited by 223 · see citing works

CFTR modulator therapy: Transforming the landscape of clinical care in cystic fibrosis

Taylor-Cousar, J. L., Robinson, P. D., Shteinberg, M., & Downey, D. G. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01609-4 · Cited by 173 · see citing works

Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials

Keating, C. L., Yonker, L. M., Vermeulen, F. L., Prais, D., Linnemann, R. W., Trimble, A. T., Kotsimbos, T. C., Mermis, J. D., Braun, A. T., O’Carroll, M., et al. (2025) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00411-9 · Cited by 132 · see citing works

Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one <i>F508del</i> allele: 144-week interim results from a 192-week open-label extension study

Daines, C. L., Tullis, E., Costa, S., Linnemann, R. W., Mall, M. A., McKone, E. F., Polineni, D., Quon, B. S., Ringshausen, F. C., Rowe, S. M., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.02029-2022 · Cited by 100 · see citing works

Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues

Burgel, P., Southern, K. W., Addy, C., Battezzati, A., Berry, C. A., Bouchara, J., Brokaar, E. J., Brown, A. W., Azevedo, P., Durieu, I., et al. (2024) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2024.01.005 · Cited by 94 · see citing works

Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial

Hoppe, J. E., Kasi, A. S., Pittman, J. E., Jensen, R., Thia, L. P., Robinson, P. J., Tirakitsoontorn, P., Ramsey, B. W., Mall, M. A., Taylor‐Cousar, J. L., et al. (2025) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00407-7 · Cited by 69 · see citing works

The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study

Burgel, P., Sermet‐Gaudelus, I., Girodon, E., Durieu, I., Houdouin, V., Audousset, C., Macey, J., Grenet, D., Porzio, M., Murris‐Espin, M., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00208-x · Cited by 63 · see citing works

Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy

Hisert, K. B., Birket, S. E., Clancy, J. P., Downey, D. G., Engelhardt, J. F., Fajac, I., Gray, R. D., Lachowicz-Scroggins, M. E., Mayer-Hamblett, N., Thibodeau, P. H., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00324-7 · Cited by 61 · see citing works

Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events

Ramsey, B. W., Correll, C. U., DeMaso, D. R., McKone, E. F., Tullis, E. D., Taylor‐Cousar, J. L., Chu, C., Volkova, N. V., Ahluwalia, N., Waltz, D., et al. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202308-1525oc · Cited by 57 · see citing works

Use of elexacaftor/tezacaftor/ivacaftor leads to changes in detection frequencies of Staphylococcus aureus and Pseudomonas aeruginosa dependent on age and lung function in people with cystic fibrosis

Dittrich, A., Sieber, S., Naehrlich, L., Burkhart, M., Hafkemeyer, S., & Tümmler, B. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.11.013 · Cited by 46 · see citing works

Cystic fibrosis in Europe: improved lung function and longevity – reasons for cautious optimism, but challenges remain

Kerem, E., Orenti, A., Adamoli, A., Hatziagorou, E., Naehrlich, L., & Sermet‐Gaudelus, I. (2024) · European Respiratory Journal · doi:10.1183/13993003.01241-2023 · Cited by 44 · see citing works

Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rare CFTR variants: a viewpoint

Burgel, P., Sermet‐Gaudelus, I., Girodon, E., Kanaan, R., Bihan, J. L., Remus, N., Ravoninjatovo, B., Grenet, D., Porzio, M., Houdouin, V., et al. (2024) · European Respiratory Journal · doi:10.1183/13993003.01959-2023 · Cited by 38 · see citing works

Current landscape of cystic fibrosis gene therapy

Plasschaert, L. W., MacDonald, K. D., & Moffit, J. S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1476331 · Cited by 27 · see citing works

Changing profile of bacterial infection and microbiome in cystic fibrosis: when to use antibiotics in the era of CFTR-modulator therapy

Milczewska, J., Syunyaeva, Z., Żabińska-Jaroń, A., Sands, D., & Thee, S. A. (2024) · European Respiratory Review · doi:10.1183/16000617.0068-2024 · Cited by 26 · see citing works

Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18 Years with Cystic Fibrosis and at Least One F508del Allele Receiving Elexacaftor/Tezacaftor/Ivacaftor

Terlizzi, V., Fevola, C., Presti, S., Castaldo, A., Daccò, V., Claut, L. E., Sepe, A. O., Majo, F., Casciaro, R., Esposito, I., et al. (2024) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2024.114176 · Cited by 25 · see citing works

Cystic fibrosis liver disease in the new era of cystic fibrosis transmembrane conductance regulator (CFTR) modulators

Eldredge, J. A., Oliver, M. R., & Ooi, C. Y. (2023) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2023.12.005 · Cited by 24 · see citing works

Global prevalence of CFTR variants with respect to their responsiveness to elexacaftor-tezacaftor-ivacaftor

Burgel, P., Orenti, A., Cromwell, E. A., Maçek, M., Gutierrez, H. H., Karadag, B. T., Faro, A., van Rens, J. G., Naehrlich, L., Bakkeheim, E., et al. (2025) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2025.10.007 · Cited by 22 · see citing works

Modulator-refractory cystic fibrosis: Defining the scope and challenges of an emerging at-risk population

Somerville, L., Borish, L., Imre, N., & Albon, D. P. (2024) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666241297877 · Cited by 21 · see citing works

Affordable Cystic Fibrosis (CF) Transmembrane Conductance Regulator Modulator Drugs for CF: All CF Lives Worldwide Matter!

Zampoli, M., Verstraete, J., Baird, C., Calligaro, G., & Morrow, B. M. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202307-1200vp · Cited by 21 · see citing works

One year of treatment with elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation causes a significant increase in liver biochemical indexes

Castaldo, A., Gelzo, M., Iacotucci, P., Longobardi, A., Taccetti, G., Terlizzi, V., & Carnovale, V. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1327958 · Cited by 21 · see citing works

Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del/CFTR variant genotype after elexacaftor/tezacaftor/ivacaftor treatment

Castaldo, A., Iacotucci, P., Bagnasco, S., Fevola, C., Carnovale, V., Antonelli, F., Cernera, G., Gelzo, M., & Terlizzi, V. (2024) · Scientific Reports · doi:10.1038/s41598-024-68511-7 · Cited by 21 · see citing works

Impact of the expanded label for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del variant in the USA

Cromwell, E. A., Ostrenga, J. S., Sanders, D. B., Morgan, W. J., Castellani, C., Szczesniak, R. D., & Burgel, P. (2024) · European Respiratory Journal · doi:10.1183/13993003.01146-2024 · Cited by 20 · see citing works

Impact of CFTR Modulators on Longitudinal Cystic Fibrosis Survival and Mortality: Review and Secondary Analysis

Rubin, J. L., McKinnon, C. J., Pedra, G., Morgan, D. A., Zweig, K., & Liou, T. G. (2025) · Pulmonary Therapy · doi:10.1007/s41030-025-00303-4 · Cited by 19 · see citing works

Progress of personalized medicine of cystic fibrosis in the times of efficient CFTR modulators

Tümmler, B., Pallenberg, S. T., Dittrich, A., Graeber, S. Y., Naehrlich, L., Sommerburg, O., & Mall, M. A. (2025) · Molecular and Cellular Pediatrics · doi:10.1186/s40348-025-00194-0 · Cited by 18 · see citing works

Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis: A Review of Registry-Based Evidence

Salvatore, D., & Pepe, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113978 · Cited by 18 · see citing works

The impact of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on the pulmonary microbiota

Robertson, J. K., & Goldberg, J. B. (2025) · Microbiology · doi:10.1099/mic.0.001553 · Cited by 15 · see citing works

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Healthcare Resource Utilization and Associated Costs Among People With Cystic Fibrosis in the US: A Retrospective Claims Analysis

Schechter, M. S., Anaya, N. S., Oster, G., Weycker, D. A., Wu, H., Arteaga‐Solis, E., Bagal, S., McGarry, L. J., Brunt, K. V., & Geiger, J. M. (2023) · Pulmonary Therapy · doi:10.1007/s41030-023-00241-z · Cited by 15 · see citing works

Impact of highly effective modulator therapy on chronic rhinosinusitis and health status: 2-year follow-up

Beswick, D. M., Khatiwada, A., Miller, J. E., Humphries, S. M., Wilson, A. W. M., Vladar, E. K., Lynch, D. A., & Taylor‐Cousar, J. L. (2023) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2023.09.013 · Cited by 14 · see citing works

Use of elexacaftor+tezacaftor+ivacaftor in individuals with cystic fibrosis and at least one F508del allele: a systematic review and meta-analysis

Filho, L. V. R. F. D. S., Athanazio, R. A., Tonon, C. R., Ferreira, J. C., & Tanni, S. É. (2023) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20230187 · Cited by 14 · see citing works

LONGITUDE: An observational study of the long-term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysis

Vega-Hernandez, G., MacGregor, G., Wilfin, A., Adams, F., Haugh, C., Baxter, C. A., Wöhling, H., Clarke, S. L., Charman, S. C., & Carr, S. B. (2025) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2025.04.012 · Cited by 13 · see citing works

Reported Adverse Events in Patients with CF Receiving Treatment with Elexacaftor/Tezacaftor/Ivacaftor: 5 Years Observational Study

Lucca, F., Meneghelli, I., Tridello, G., Buniotto, F., Cucchetto, G., Volpi, S., Pintani, E., Bezzerri, V., & Cipolli, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124335 · Cited by 13 · see citing works

Real-world effectiveness of elexacaftor/tezacaftor/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis

Keens, T. G., Hoffman, V., Topuria, I., Elder, K., Cerf, S., Mulder, K., Roberts, J., Lysinger, J., Reyes, M. D. C., Berdella, M. N., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28508 · Cited by 12 · see citing works

Changing Epidemiology of Pediatric Pulmonary Exacerbations in Cystic Fibrosis

Fireizen, Y., Ahmed, M., Vigers, T., Akong, K., Ryu, J., Hahn, A., Fanous, H., Koumbourlis, A. C., Tirakitsoontorn, P., Arrieta, A. C., et al. (2025) · Pediatric Pulmonology · doi:10.1002/ppul.71019 · Cited by 11 · see citing works

Therapeutic Drug Monitoring of Elexacaftor, Tezacaftor, and Ivacaftor in Adult People with Cystic Fibrosis

Naehrig, S., Shad, C., Breuling, M., Goetschke, M., Habler, K., Sieber, S., Kastenberger, J., Kunzelmann, A. K., Sommerburg, O., Liebchen, U., et al. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14101065 · Cited by 11 · see citing works

Cystic fibrosis liver disease in the post-modulator era

Narkewicz, M. R. (2023) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001017 · Cited by 10 · see citing works

Dried Blood Spot Method Development and Clinical Validation for the Analysis of Elexacaftor, Elexacaftor-M23, Tezacaftor, Tezacaftor-M1, Ivacaftor, Ivacaftor Carboxylate, and Hydroxymethyl Ivacaftor Using LC-MS/MS

Vonk, S. E. M., van der Meer‐Vos, M., Kos, R., Neerincx, A. H., Terheggen‐Lagro, S. W. J., Altenburg, J., der Zee, A. H. M., Mathôt, R. A. A., & Kemper, E. M. (2024) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001231 · Cited by 10 · see citing works

Real-world pharmacokinetics of elexacaftor-tezacaftor-ivacaftor in children with cystic fibrosis: a prospective observational study

Vonk, S. E. M., Terheggen‐Lagro, S. W. J., Haarman, E. G., Hashimoto, S., der Zee, A. H. M., Mathôt, R. A. A., & Kemper, E. M. (2025) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2025.03.008 · Cited by 10 · see citing works

Managing an ageing cystic fibrosis population: challenges and priorities

Frost, F. J., Peckham, D. G., Felton, I. C., Snowball, J., Gray, R. D., Jones, A. M., Simmonds, N. J., Lord, R. W., Lip, G. Y. H., Chandler, H., et al. (2025) · European Respiratory Review · doi:10.1183/16000617.0261-2024 · Cited by 10 · see citing works

Unplanned pregnancies following the introduction of elexacaftor/tezacaftor/ivacaftor therapy in women with cystic fibrosis

Daccò, V., Alicandro, G., Trespìdi, L., Gramegna, A., & Blasi, F. (2023) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-023-07153-y · Cited by 10 · see citing works

Body mass, linear growth, and body composition before and after the introduction of elexacaftor/tezacaftor/ivacaftor among children and adults with cystic fibrosis

Bader-Larsen, K. S., Nielsen, B. U., Henriksen, E., Bryrup, T., Leo-Hansen, C., Mathiesen, I. H. M., Faurholt-Jepsen, D., Qvist, T., Oturai, P., Langdahl, B. L., et al. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.09.008 · Cited by 9 · see citing works

Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis and rare CFTR variants: in vitro translation to a phase 3, double-blind, randomized, placebo-controlled trial, and real-world study

Castellani, C., Mondéjar-López, P., Goor, F. V., Quon, B., Alghisi, F., Fabrizzi, B., Ramsey, B. W., Taylor-Cousar, J. L., McKone, E. F., Tullis, E. W., et al. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamaf001 · Cited by 9 · see citing works

Aspergillus in Children and Young People with Cystic Fibrosis: A Narrative Review

Chesshyre, E. L. D., Wooding, E. L., Sey, E. A., & Warris, A. (2025) · Journal of Fungi · doi:10.3390/jof11030210 · Cited by 8 · see citing works

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Microbiology and Antibiotic Utilization in People With Cystic Fibrosis

Williams, C. L., Billings, J., McGowan, H., McDevitt, R., Esther, C. R., McKinzie, C. J., Wilson, W. S., & Kam, C. W. (2025) · Pediatric Pulmonology · doi:10.1002/ppul.71038 · Cited by 8 · see citing works

Lung function improvement on triple modulators: high-resolution, nationwide data from the Danish Cystic Fibrosis Cohort

Leo‐Hansen, C., Faurholt‐Jepsen, D., Qvist, T., Højte, C., Nielsen, B. U., Bryrup, T., Henriksen, E. H., Katzenstein, T. L., Skov, M., Mathiesen, I. H. M., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00339-2024 · Cited by 8 · see citing works

Management of liver disease and portal hypertension in cystic fibrosis: a review

Colombo, C. M., Lanfranchi, C., Tosetti, G., Corti, F., & Primignani, M. (2024) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2024.2365842 · Cited by 8 · see citing works

Nasal Epithelium Transcriptomics Predict Clinical Response to Elexacaftor/Tezacaftor/Ivacaftor

Yue, M., Weiner, D. J., Gaietto, K. M., Rosser, F. J., Qoyawayma, C., Manni, M. L., Myerburg, M. M., Pilewski, J. M., Celedon, J. C., Chen, W., et al. (2024) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2024-0103oc · Cited by 8 · see citing works

The cost of simplifying treatments for cystic fibrosis: Implications of the SIMPLIFY trial

Gold, L. S., Hansen, R. N., Mayer-Hamblett, N., Nichols, D. P., Gifford, A. H., Kloster, M., Goss, C. H., & Kessler, L. G. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.30.1.26 · Cited by 8 · see citing works

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial

Durieu, I., Clements, B. S., Fabrizzi, B., Mall, M. A., McKone, E. F., Ramsey, B. W., Tullis, E. D., Taylor‐Cousar, J. L., van der Meer, R., Bachman, E. S., et al. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202411-2312oc · Cited by 7 · see citing works

Severe hepatotoxicity is uncommon following the introduction of Elexacaftor/Tezacaftor/Ivacaftor: A real-world two-years follow-up study of the Danish cystic fibrosis cohort

Højte, C., Olsen, M. F., Faurholt‐Jepsen, D., Jørgensen, M. H., Pressler, T., Leo‐Hansen, C., Bryrup, T., Jeppesen, M., Olesen, H. V., Petersen, J., et al. (2025) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2025.08.008 · Cited by 6 · see citing works

Real-World Safety and Effectiveness of Elexacaftor, Tezacaftor, and Ivacaftor in People with Cystic Fibrosis and Advanced Lung Disease: A Two-Year Multicenter Cohort Study

Volpi, S., Ambroni, M., Buzzetti, R., Cimino, G. G., Gramegna, A., Lucanto, M. C., Ripani, P., Ros, M., Salvatore, D., Spada, E., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110513 · Cited by 6 · see citing works

Impact of age at ivacaftor initiation on pulmonary outcomes among people with cystic fibrosis

Merlo, C. A., McGarry, L. J., Thorat, T., Nguyen, C., DerSarkissian, M., Muthukumar, A., Healy, J., Brookhart, M. A., & Rubin, J. L. (2024) · Thorax · doi:10.1136/thorax-2023-220559 · Cited by 6 · see citing works

Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis with Mildly Decreased and Normal Lung Function: A Real-Life Observational Study

Yaacoby‐Bianu, K., Dagan, A., Cohen‐Cymberknoh, M., Tsviban, L., Gur, M., Golan‐Tripto, I., Aviram, M., Stein, N., Shteinberg, M., Kerem, E., et al. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202401-030rl · Cited by 6 · see citing works

CFTR dysfunction leads to defective bacterial eradication on cystic fibrosis airways

Wu, M., & Chen, J.-H. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1385661 · Cited by 5 · see citing works

Comparative Efficacy of CFTR Modulators: A Network Meta-analysis

IFTIKHAR, I. H., Rao, S. T., Nadama, R., Janahi, I. A., & BaHammam, A. S. (2025) · Lung · doi:10.1007/s00408-025-00802-w · Cited by 5 · see citing works

Impact of availability of a highly effective cystic fibrosis treatment (elexacaftor/tezacaftor/ivacaftor) on lung transplant waitlist and lung transplantation trends in the US

Merlo, C. A., Geiger, J. M., Wang, Z., Lyden, G. R., Schladt, D. P., & McGarry, L. J. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108171 · Cited by 5 · see citing works

Real-world effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis patients with Phe508del -gating and -residual function genotypes

Salvatore, D., Iacotucci, P., Pepe, A., Terminiello, A., Majo, F., Carnovale, V., Vitullo, P., Messore, B., Parisi, G. F., Calderazzo, M. A., et al. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108221 · Cited by 5 · see citing works

Elexacaftor–tezacaftor–ivacaftor use after solid organ transplant

Kapnadak, S. G., & Ramos, K. J. (2024) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001110 · Cited by 5 · see citing works

Longitudinal Study on Clinical Predictors for Allergic Bronchopulmonary Aspergillosis in Children and Young People with Cystic Fibrosis Highlights the Impact of Infection with Aspergillus and Pseudomonas and Ivacaftor Treatment

Chesshyre, E. L. D., Enderby, B., Shore, A. C., Warren, F. C., & Warris, A. (2025) · Journal of Fungi · doi:10.3390/jof11020116 · Cited by 5 · see citing works

Comprehensive Evaluation of Elexacaftor/Tezacaftor/Ivacaftor in Paediatric Cystic Fibrosis: Nutritional, Pulmonary, and Quality-of-Life Outcomes

Walicka‐Serzysko, K., Postek, M., Mielus, M., Borawska-Kowalczyk, U., Milczewska, J., Zybert, K., Woźniacki, Ł., Wołkowicz, A., & Sands, D. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14227969 · Cited by 4 · see citing works

Elexacaftor/tezacaftor/ivacaftor, a game-changer in cystic fibrosis: The Portuguese experience

FRAGOSO, E. C., Boaventura, R. D. P., Almeida, L., Amorim, A. A., Gamboa, F., Santos, A. S., Gonçalves, F., Cruz, C. M., Carreiro, A., Gonçalves, A. S., et al. (2024) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2024.102328 · Cited by 4 · see citing works

Exploring reduced pulmonary exacerbation rates in cystic fibrosis: a pandemic or modulator effect?

Stephenson, A. L., Sykes, J. R., Stanojevic, S., Ma, X., Ostrenga, J., Todd, J., Faro, A., Elbert, A., Marshall, B. C., Ramos, K. J., et al. (2025) · ERJ Open Research · doi:10.1183/23120541.00111-2025 · Cited by 4 · see citing works

Blood platelet reduction after elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis may depend on systemic inflammation reduction

Castaldo, A., Cimbalo, C., Fevola, C., Carnovale, V., Iacotucci, P., Raia, V., Terlizzi, V., Gelzo, M., Sepe, A. O., & Tosco, A. (2025) · Scientific Reports · doi:10.1038/s41598-025-12333-8 · Cited by 4 · see citing works

Epidemiology of advanced cystic fibrosis lung disease in the modulator era

Westhoff, J., & Naehrlich, L. (2024) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001115 · Cited by 4 · see citing works

Long-term outcomes in people with CF lacking FEV1 response to elexacaftor/tezacaftor/ivacaftor therapy

Hadhud, M., Halevy, D., Reiter, J. M., Ben-Meir, E., Gileles‐Hillel, A., Sadras, I., Kerem, E., Cohen‐Cymberknoh, M., & Breuer, O. (2025) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2025.05.005 · Cited by 3 · see citing works

The treatment with Elexacaftor/Tezacaftor/Ivacaftor significantly increases serum bilirubin and decreases blood platelets in children and adolescents with cystic fibrosis homozygous or double heterozygous for the F508del CFTR variant

Castaldo, A., Cimbalo, C., Fevola, C., Raia, V., Terlizzi, V., Gelzo, M., Sepe, A. O., & Tosco, A. (2025) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2025.10.001 · Cited by 3 · see citing works

Real-World Impact of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Italy: A Retrospective Study from a Cystic Fibrosis Center

Cipolli, M., Thorat, T., Pafundi, P. C., Roggeri, A., Roggeri, D. P., Rossi, C., Pintani, E., Meneghelli, I., Lucca, F., Fratoni, A., et al. (2025) · Pulmonary Therapy · doi:10.1007/s41030-025-00334-x · Cited by 3 · see citing works

Real-World Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis: A 24-Month Italian National Registry Study

Salvatore, D., Campagna, G., Padoan, R., Pepe, A., Amato, A., & Salvatore, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15072699 · Cited by 3 · see citing works

Racial disparities in lung transplantation for cystic fibrosis in the era of highly effective modulator therapy

Ruck, J. M., Feng, S. N., Toporek, A. H., Shah, P. D., Tallarico, E., Lechtzin, N., Massie, A. B., Segev, D. L., Bush, E. L., & Merlo, C. A. (2025) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2025.01.006 · Cited by 3 · see citing works

Qualitative Analysis of Perspectives on Lung Transplant among People with Cystic Fibrosis

Milinic, T., Hobler, M. R., Bartlett, L., Gill, E. R., Burdis, N., Engelberg, R. A., Curtis, J. R., Hartzler, A. L., Aitken, M. L., Kapnadak, S. G., et al. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202307-625oc · Cited by 3 · see citing works

Chronic daily respiratory care needs in people with cystic fibrosis treated with highly effective cystic fibrosis transmembrane conductance regulator modulators

Wajda, K. E., Roesch, E. A., & Gifford, A. H. (2023) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001006 · Cited by 3 · see citing works

Cystic fibrosis year in review 2023

Swetland, D. V., & Savant, A. P. (2024) · Pediatric Pulmonology · doi:10.1002/ppul.27190 · Cited by 3 · see citing works

Letter to the editor: A contemporary assessment of CFTR modulator use and eligibility

Rubin, J. L., & Kreindler, J. L. (2024) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2024.02.014 · Cited by 3 · see citing works

Outcomes of Modulator Therapy Discontinued After Short‐Term Use in Adult Cystic Fibrosis

Karcıoğlu, O., İdikut, A., Öztürk, E., & Damadoğlu, E. (2024) · Pediatric Pulmonology · doi:10.1002/ppul.27416 · Cited by 2 · see citing works

Long-term exercise capacity in paediatric cystic fibrosis: a modern era perspective

Gaupmann, R., Stöger, L., Schmidthaler, K., Pauger, B., Mersi, B., Graf, A. C., Szépfalusi, Z., Renner, S., Dehlink, E., & Gruber, S. (2025) · ERJ Open Research · doi:10.1183/23120541.00971-2024 · Cited by 2 · see citing works

The Changing Transplant Landscape in the Era of Elexacaftor/Tezacaftor/Ivacaftor: A Word of Caution

Semenchuk, J. A., Tuff-Gordon, E., Ma, X., Sykes, J. R., Cheng, S. Y., Aversa, M. M., Chaparro, C., Tullis, E. D., & Stephenson, A. L. (2025) · Clinical Transplantation · doi:10.1111/ctr.70317 · Cited by 2 · see citing works

Long-term impact of elexacaftor/tezacaftor/ivacaftor on small and large airways in people with cystic fibrosis aged ≥6 years: 24-month real-world evidence from the German Cystic Fibrosis Registry

Dillenhöfer, S., Schütz, K., Burkhart, M., Ellemunter, H., Kappler, M., Sieber, S., Naehrlich, L., Brinkmann, F., Sutharsan, S., & German CF Registry of the Mukoviszidose e.V. (2025) · ERJ Open Research · doi:10.1183/23120541.00813-2025 · Cited by 2 · see citing works

Real-world outcomes after initiation of Elexacaftor/tezacaftor/ivacaftor in an adolescent cohort with cystic fibrosis

Johnston, J. R., Donnelley, M., Smith, R., Louise, J., Grunert, J., Vanda, C. L., & Tai, A. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108410 · Cited by 2 · see citing works

Comparison of interrupted and continuous modulator therapy in cystic fibrosis: a real life experience in Turkey

Ergenekon, P., Selçuk, M., Ünal, G., Bayramoğlu, G. G., Altuntaş, C., Köse, M., Başaran, A. E., Oksay, S. C., Uytun, S., Öktem, S., et al. (2025) · Frontiers in Pediatrics · doi:10.3389/fped.2025.1659633 · Cited by 2 · see citing works

Improvement of Cystic Fibrosis-Associated Liver Disease in Adults on Long-Term Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators

Manioudaki, S., Vasilieva, L., Geladari, E. V., Mani, I., Athanassa, Z., Elefsiniotis, I. S., Hadziyannis, E. S., Sevastianos, V., Oikonomou, A., Theophilou, A., et al. (2025) · Life · doi:10.3390/life15121794 · Cited by 2 · see citing works

Elexacaftor/Tezacaftor/Ivacaftor Effectiveness in N1303K Variant in Adult People With Cystic Fibrosis

Canan, M. G. M., Sokoloski, C. S., Severo, C. R., Rached, S. Z., & Athanazio, R. A. (2024) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2024.04.007 · Cited by 2 · see citing works

Exploring the effects of pulmonary rehabilitation and its determinants in lung transplant candidates with cystic fibrosis

Nicholson, J. M., Goldstein, R. S., Nourouzpour, S., Elangeswaran, B., Munawar, M., Wickerson, L. M., Keshavjee, S. H., Tullis, E. D., Chaparro, C., & Rozenberg, D. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.107982 · Cited by 2 · see citing works

Unveiling the psychosocial impact of Elexacaftor/Tezacaftor/Ivacaftor therapy in Cystic Fibrosis patients

García, M. S., Peláez, A., Gómez-Punter, R. M., López, M. C., Carbajal, C. M., Ancochea, J., Bachiller, J. M. E., Hernández, A. S. M., Rodrigo-García, M., Clemente, M. M. G., et al. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03455-2 · Cited by 2 · see citing works

Cystic fibrosis and other ion channel-related diseases

Graeber, S. Y., & Mall, M. A. (2023) · European Respiratory Society eBooks · doi:10.1183/2312508x.10018022 · Cited by 2 · see citing works

Median age of survival in the 80s! Is there sufficient evidence to believe it?

Stanojevic, S., Mayer-Hamblett, N., Szczesniak, R. D., Cromwell, E. A., & Keogh, R. H. (2023) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2023.06.004 · Cited by 2 · see citing works

Cast no shadow: assessing the disease-modifying effects of elexacaftor/tezacaftor/ivacaftor

Barry, P. J., & Burgel, P. (2023) · European Respiratory Journal · doi:10.1183/13993003.02026-2023 · Cited by 2 · see citing works

The course of cystic fibrosis in adult patients with Burkholderia cepacia complex infection

Afanaseva, M. V., Krasovskiy, S., & Amelina, E. (2025) · PULMONOLOGIYA · doi:10.18093/0869-0189-2025-35-2-241-253 · Cited by 1 · see citing works

Highly Effective Modulator Therapy in Cystic Fibrosis: Addressing Unusual Variants in the Middle East

Isse, S., Wahla, A. S., Uzbeck, M. H., Zoumot, Z., Abuzakouk, M., & Shafiq, I. (2025) · Pulmonary Medicine · doi:10.1155/pm/3622052 · Cited by 1 · see citing works

An update on cystic fibrosis Hepato-biliary involvement

Freeman, A. J., & Bodewes, F. A. J. A. (2026) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2026.03.022 · Cited by 1 · see citing works

Changes in anthropometric parameters in children with cystic fibrosis treated with ivacaftor/tezacaftor/ elexacaftor and ivacaftor, with transition within a single INN, in the Republic of Bashkortostan

Валеева, Д. С., & Trofimova, V. G. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-289 · Cited by 1 · see citing works

Efficacy of Trikafta (ELX/TEZ/IVA) & Symdeko (TEZ/IVA) in Treating Cystic Fibrosis with F508del Allele: A Systematic Review and Meta-analysis

Hussain, K., Karhana, S., Garg, A., & Khan, M. A. (2025) · Thoracic research and practice · doi:10.4274/thoracrespract.2025.2025-1-1 · Cited by 1 · see citing works

Evaluating Long-Term Effectiveness of Cystic Fibrosis Modulator Therapies after Rapid Adoption: A Dual-Approach Study

Afonso, P. M., Zhou, G. C., Su, W., Burgel, P., Cromwell, E. A., Goss, C. H., Keogh, R. H., Liou, T. G., Marshall, B. C., Mayer-Hamblett, N., et al. (2025) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202503-267oc · Cited by 1 · see citing works

Long-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor on Nocturnal Cardiorespiratory Polygraphy Parameters in Patients with Cystic Fibrosis: A Prospective Study

Tosto, M., Parisi, G. F., Presti, S., Papale, M. R., Pecora, G., Mulè, E., Ornato, V., Aloisio, D., Manti, S., & Leonardi, S. (2025) · Life · doi:10.3390/life15121942 · Cited by 1 · see citing works

The impact of elexacaftor–tezacaftor–ivacaftor on cardiometabolic risk factors: a systematic review

Girouard, H., Jaber, F., Gharib, J., Boudreau, V., Alexandre‐Heymann, L., & Coriati, A. (2026) · European Respiratory Review · doi:10.1183/16000617.0197-2025 · Cited by 1 · see citing works

Pseudomonas aeruginosa lasR mutants resist phagocytosis and alter inflammatory cytokine production by cystic fibrosis macrophages

Aridgides, D. S., Mellinger, D., Gwilt, L. L., Correia, A. R., Finger, C. E., Goddard, J., Hampton, T. H., Mould, D. L., Hogan, D. A., & Ashare, A. (2026) · mSphere · doi:10.1128/msphere.00702-25 · Cited by 1 · see citing works

Triglyceride-related lipid changes in adults with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor: A real-world cross-sectional study

Zamarrón, E., Cuadrado, A. P., Baloira, L., Carpio, C., García, I. A., Milla, S. P., de Villar, N. G. P., Mangas, A., Aguilar, P. M., Walther, R. Á.-S., et al. (2026) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2026.103275 · Cited by 1 · see citing works

CFTR modulator therapy reshapes airway inflammation in cystic fibrosis: Insights from proteomics and machine learning

Årman, F., Diemer, S., Happonen, L., & Påhlman, L. I. (2026) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2026.05.002 · Cited by 1 · see citing works

Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: Impact on Hospitalizations and Health Care Resource Utilization in a Universal Health Care Setting

Råket, H. K., Ankarfeldt, M. Z., Wang, J. N., Pressler, T., Jensen‐Fangel, S., Qvist, T., Faurholt‐Jepsen, D., Jimenez‐Solem, E., Petersen, J., Jensen, C. B., et al. (2025) · Pulmonary Therapy · doi:10.1007/s41030-025-00287-1 · Cited by 1 · see citing works

Duodenal Ulcer in a Child With Cystic Fibrosis on Elexacaftor-Tezacaftor-Ivacaftor Therapy: A Casual Association or a Possible Adverse Event?

Terlizzi, V., Benedetto, M. D. D., Renzo, S., Galici, V., Scarallo, L., Mainz, J. G., & Lionetti, P. (2025) · Clinical Therapeutics · doi:10.1016/j.clinthera.2025.04.002 · Cited by 1 · see citing works

Breath of fresh insight: unraveling the evolution of our understanding of cystic fibrosis pulmonary exacerbations

Somayaji, R., & Quon, B. S. (2023) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001010 · Cited by 1 · see citing works

Reducing treatment burden in the era of CFTR modulators – Authors' reply

Gifford, A. H., Mayer-Hamblett, N., & Nichols, D. P. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00224-2 · Cited by 1 · see citing works

LONGITUDE: An observational study of the long-term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysis

Vega-Hernandez, G., MacGregor, G., Wilfin, A., Adams, F., Haugh, C., Baxter, C. A., Wöhling, H., Clarke, S. L., Charman, S. C., & Carr, S. B. (2025) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2025.04.012 · Cited by 13 · see citing works

EPS2.05LONGITUDE-Non-F: an observational study evaluating outcomes of ELX/TEZ/IVA in people with cystic fibrosis aged ≥6 years with non-F508del CFTR variants using data from the UK CF Registry

Baxter, C. A., Duckers, J. M., Muller, E., Milovic, J., Adams, F., Clarke, S. L., Charman, S. C., & Vega-Hernandez, G. (2025) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2025.03.602

Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3 Open-Label Extension Study

Daines, C. L., Polineni, D., Tullis, E. D., Costa, S., Linnemann, R. W., Mall, M. A., McKone, E. F., Quon, B. S., Ringshausen, F. C., Selvadurai, H. C., et al. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202411-2231oc · Cited by 31 · see citing works

Real-world effectiveness of elexacaftor/tezacaftor/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis

Keens, T. G., Hoffman, V., Topuria, I., Elder, K., Cerf, S., Mulder, K., Roberts, J., Lysinger, J., Reyes, M. D. C., Berdella, M. N., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28508 · Cited by 12 · see citing works

WS16.03 Registry-based study of people with cystic fibrosis (pwCF) treated with elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA): Up to 2 years of real-world outcome data

Bower, J. K., Chang, C. Y., Sahota, G., Chin, A., Ahluwalia, N., Chu, C., Weinstock, T. G., Ostrenga, J. S., Regenfuß, N., & Naehrlich, L. (2023) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(23)00273-4